Colin Bristow
Stock Analyst at UBS
(1.68)
# 3,409
Out of 5,129 analysts
105
Total ratings
40.32%
Success rate
-3.49%
Average return
Main Sectors:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Neutral | $4 → $10 | $9.53 | +4.93% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $463.48 | +17.80% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $147.23 | -23.93% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $72.14 | +10.90% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.24 | +54.32% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $2.55 | -60.78% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $26.68 | -36.28% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $364.65 | -12.52% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $2.47 | +61.94% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $27.61 | +1.41% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $117.15 | +2.43% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $188.99 | +6.88% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.66 | +863.86% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $754.91 | +45.58% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $18.33 | +811.07% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $1,025.00 | -59.02% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $11.17 | -82.09% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.01 | +795.52% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $222.44 | -34.36% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $60.86 | +23.23% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $1.84 | +1,313.04% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.76 | +56.25% | 1 | Aug 23, 2021 |
enGene Holdings
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $9.53
Upside: +4.93%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $463.48
Upside: +17.80%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $147.23
Upside: -23.93%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $72.14
Upside: +10.90%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.24
Upside: +54.32%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $2.55
Upside: -60.78%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $26.68
Upside: -36.28%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $364.65
Upside: -12.52%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $2.47
Upside: +61.94%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $27.61
Upside: +1.41%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $117.15
Upside: +2.43%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $188.99
Upside: +6.88%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.66
Upside: +863.86%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $754.91
Upside: +45.58%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $18.33
Upside: +811.07%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $1,025.00
Upside: -59.02%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $11.17
Upside: -82.09%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.01
Upside: +795.52%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $222.44
Upside: -34.36%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $60.86
Upside: +23.23%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $1.84
Upside: +1,313.04%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $5.76
Upside: +56.25%